These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 27757559)

  • 1. 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.
    Stern PL; Harrop R
    Cancer Immunol Immunother; 2017 Apr; 66(4):415-426. PubMed ID: 27757559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding and exploiting 5T4 oncofoetal glycoprotein expression.
    Stern PL; Brazzatti J; Sawan S; McGinn OJ
    Semin Cancer Biol; 2014 Dec; 29():13-20. PubMed ID: 25066861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer.
    Woods AM; Wang WW; Shaw DM; Ward CM; Carroll MW; Rees BR; Stern PL
    Biochem J; 2002 Aug; 366(Pt 1):353-65. PubMed ID: 12003637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.
    Cappuccini F; Pollock E; Stribbling S; Hill AVS; Redchenko I
    Oncotarget; 2017 Jul; 8(29):47474-47489. PubMed ID: 28537896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy.
    Griffiths RW; Gilham DE; Dangoor A; Ramani V; Clarke NW; Stern PL; Hawkins RE
    Br J Cancer; 2005 Sep; 93(6):670-7. PubMed ID: 16222313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL12 receptor preference, signal transduction, biological response and the expression of 5T4 oncofoetal glycoprotein.
    McGinn OJ; Marinov G; Sawan S; Stern PL
    J Cell Sci; 2012 Nov; 125(Pt 22):5467-78. PubMed ID: 22956548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.
    Xu Y; Morales AJ; Cargill MJ; Towlerton AMH; Coffey DG; Warren EH; Tykodi SS
    Cancer Immunol Immunother; 2019 Dec; 68(12):1979-1993. PubMed ID: 31686124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells.
    Southgate TD; McGinn OJ; Castro FV; Rutkowski AJ; Al-Muftah M; Marinov G; Smethurst GJ; Shaw D; Ward CM; Miller CJ; Stern PL
    PLoS One; 2010 Apr; 5(4):e9982. PubMed ID: 20376365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pattern of expression of the 5T4 oncofoetal antigen on normal, dysplastic and malignant oral mucosa.
    Ali A; Langdon J; Stern P; Partridge M
    Oral Oncol; 2001 Jan; 37(1):57-64. PubMed ID: 11120484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4.
    Shaw DM; Embleton MJ; Westwater C; Ryan MG; Myers KA; Kingsman SM; Carroll MW; Stern PL
    Biochim Biophys Acta; 2000 Dec; 1524(2-3):238-46. PubMed ID: 11113573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.
    Forsberg G; Ohlsson L; Brodin T; Björk P; Lando PA; Shaw D; Stern PL; Dohlsten M
    Br J Cancer; 2001 Jul; 85(1):129-36. PubMed ID: 11437414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastasis-associated 5T4 oncofoetal antigen is concentrated at microvillus projections of the plasma membrane.
    Carsberg CJ; Myers KA; Evans GS; Allen TD; Stern PL
    J Cell Sci; 1995 Aug; 108 ( Pt 8)():2905-16. PubMed ID: 7593330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
    Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
    J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy success in prophylaxis cannot predict therapy: prime-boost vaccination against the 5T4 oncofoetal antigen.
    Ali S; Mulryan K; Taher T; Stern PL
    Cancer Immunol Immunother; 2007 Feb; 56(2):165-80. PubMed ID: 16758205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.
    Castro FV; Al-Muftah M; Mulryan K; Jiang HR; Drijfhout JW; Ali S; Rutkowski AJ; Kalaitsidou M; Gilham DE; Stern PL
    Cancer Immunol Immunother; 2012 Jul; 61(7):1005-18. PubMed ID: 22127365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5T4 oncotrophoblast glycoprotein: janus molecule in life and a novel potential target against tumors.
    Zhao Y; Wang Y
    Cell Mol Immunol; 2007 Apr; 4(2):99-104. PubMed ID: 17484803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
    Al-Taei S; Salimu J; Lester JF; Linnane S; Goonewardena M; Harrop R; Mason MD; Tabi Z
    Lung Cancer; 2012 Aug; 77(2):312-8. PubMed ID: 22498111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells.
    Guo X; Zheng H; Luo W; Zhang Q; Liu J; Yao K
    Sci Rep; 2017 Jul; 7(1):4859. PubMed ID: 28687750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design.
    Besneux M; Greenshields-Watson A; Scurr MJ; MacLachlan BJ; Christian A; Davies MM; Hargest R; Phillips S; Godkin A; Gallimore A
    Cancer Immunol Immunother; 2019 Feb; 68(2):247-256. PubMed ID: 30406375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.
    Mulryan K; Ryan MG; Myers KA; Shaw D; Wang W; Kingsman SM; Stern PL; Carroll MW
    Mol Cancer Ther; 2002 Oct; 1(12):1129-37. PubMed ID: 12481437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.